On April 27, Comorbid Patients School Conference was held at Medicina Clinic, supported by Pfizer


On April 27, Comorbid Patients School Conference was held at Medicina Clinic, supported by Pfizer

On April 27, scientific and educational conference entitled “Comorbid Patient’s School” was held. At the conference, presentations were delivered by scientists, cardiologists, immunologists, general practitioners and gerontologists. The program included a discussion of anticoagulant therapy and risks of cardiovascular diseases in comorbid patients. Over 60 doctors participated in the conference. The event was supported by Pfizer.

At the conference, scientists and physicians discussed how multiple factors could be combined into a general picture of the disease of one patient and how to handle all this, how to correctly and timely identify risks in a comorbid patient, take measures to prevent thromboembolism, and rationally prescribe anticoagulant therapy.

There is a number of rules to be followed by a practitioner when formulating a clinical diagnosis for a comorbid patient.The main rule is isolation of the underlying disease and background diseases, as well as their complications and concomitant pathologies in the structure of diagnosis.

At the conference, reports were delivered by renowned experts, such as D.U. Akasheva, Candidate of Medical Sciences, Lead Researcher of the Department for the Study of the Problems of Aging and Prevention of Age-Associated Diseases, State Research Center of Preventive Medicine (Ministry of Health of the Russian Federation); D.A. Napalkov, Doctor of Medical Sciences, Professor of the Department of Faculty Therapy No. 1, the I.M. Sechenov First Moscow State Medical University; A.V. Rodionov, cardiologist and therapist, member of the Moscow branch of the Interregional Society of Evidence-Based Medicine, the All-Russian Scientific Society of Cardiologists (VNOK), the National Society for the Study of Atherosclerosis (NOA) and the European Society of Cardiology (ESC); and D.V. Pakhomov, allergologist-immunologist, vaccinologist of the laboratory of vaccination and immunotherapy against allergic diseases, the I.I.Mechnikov Scientific Research Institute of Vaccines and Serums of the Russian Academy of Medical Sciences.

In 1970, Alvan Feinstein proposed the concept of comorbidity (Latin co - together and morbus - disease). Under this term, he implied the presence of an additional clinical picture that already exists or can appear independently, in addition to the current disease, and always differs from the current disease. Comorbidity was demonstrated by Professor Feinstein on the example of somatic patients with acute rheumatic fever: he discovered that patients suffering from several diseases at the same time had a worse prognosis. After its discovery, comorbidity formed a separate field of research.

The main idea behind the school is that there are no separate diseases.However, often doctors prevent, diagnose and treat a patient's disease in isolation, paying insufficient attention to the diseases suffered by the patient in the past and to the patients concomitant pathologies. It would be more reasonable to consider current disease and look for approaches to treat it in conjunction with analysis of diseases in the past, risk factors and predictors observed in the patient, as well as the probability of potential complications.